Comparative Pharmacology
Head-to-head clinical analysis: OPTIRAY 160 versus OPTIRAY 300.
Head-to-head clinical analysis: OPTIRAY 160 versus OPTIRAY 300.
OPTIRAY 160 vs OPTIRAY 300
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Radiopaque contrast agent that attenuates X-rays, providing enhanced visualization of vascular structures and organs during imaging procedures.
Optiray 300 (ioversol) is a nonionic iodinated contrast medium that attenuates X-rays, enhancing vascular and tissue contrast during imaging. It acts by increasing the density of blood vessels and tissues to X-rays, thereby improving visualization of anatomical structures.
Intravenous: 50-150 mL (total dose 8-30 g iodine) as a bolus or rapid infusion; Intra-arterial: Variable per procedure; maximum 250 mL per procedure.
Intravenous administration: 50-150 mL per injection (up to 250 mL for CT imaging). Typical adult dose: 1-2 mL/kg body weight (up to 150 mL) given as a bolus or rapid infusion. Intrathecal administration: 8-12 mL for myelography.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5 to 2 hours in patients with normal renal function. Prolonged in renal impairment, up to 20–30 hours in severe renal failure.
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function. In patients with impaired renal function, half-life may be prolonged significantly (up to 30 hours or more), necessitating dose adjustment or avoidance.
Primarily renal excretion via glomerular filtration; approximately 95% of the administered dose is excreted unchanged in the urine within 24 hours. Fecal excretion is negligible (<1%).
Primarily renal elimination via glomerular filtration; approximately 95-100% of the administered dose is excreted unchanged in urine within 24 hours. A negligible amount is eliminated via biliary/fecal routes (<1%).
Category C
Category C
Radiological Contrast Agent
Radiological Contrast Agent